Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Core Insights - Soligenix, Inc. has received a $2.6 million FDA Orphan Products Development grant to support the evaluation of HyBryte™ for extended treatment in early-stage cutaneous T-cell lymphoma (CTCL) patients [14] - Initial results from an open-label, investigator-initiated study (IIS) indicate that 75% of patients treated with HyBryte™ for at least 12 weeks achieved "Treatment Success," defined as a ≥50% improvement in their cumulative mCAILS score [3][4] - The company plans to initiate a confirmatory Phase 3 study, FLASH2, by the end of 2024, which will replicate the successful design of the previous Phase 3 FLASH study [12][13] Company Overview - Soligenix is a late-stage biopharmaceutical company focused on developing treatments for rare diseases with unmet medical needs, particularly through its Specialized BioTherapeutics segment [16] - The company is advancing HyBryte™ (SGX301), a novel photodynamic therapy utilizing synthetic hypericin, for the treatment of CTCL [16] - The company also has other development programs targeting conditions such as psoriasis and inflammatory diseases [16] Clinical Study Details - The IIS evaluating HyBryte™ treatment involves up to 50 patients, with a primary endpoint of achieving a ≥50% reduction in the cumulative mCAILS score [5] - The Phase 3 FLASH study enrolled 169 patients, demonstrating a 16% response rate for HyBryte™ compared to 4% for placebo at 8 weeks [8] - In the second treatment cycle of the FLASH study, a 40% response rate was observed among patients receiving 12 weeks of HyBryte™ treatment [9] Treatment Mechanism and Safety - HyBryte™ is a first-in-class therapy that uses visible light to activate synthetic hypericin, which targets malignant T-cells while minimizing the risk of secondary malignancies associated with traditional therapies [6][11] - The treatment has shown a favorable safety profile, with no treatment-related adverse events reported to date [3][11] - The mechanism of action of HyBryte™ is not associated with DNA damage, making it a safer alternative to existing therapies [11] Market Context - CTCL is a rare form of non-Hodgkin's lymphoma, affecting approximately 31,000 individuals in the U.S. and 38,000 in Europe, with a significant unmet medical need for effective treatments [15][19] - The FDA and EMA have indicated that a second successful Phase 3 trial is required for marketing approval, which Soligenix is preparing to initiate [12][13]